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Abstract
Cancer cell resistance to anoikis driven by aberrant signaling sustained by the tumor microenvironment confers high
invasive potential and therapeutic resistance. We recently generated a novel lead quinazoline-based DoxazosinH derivative,
DZ-50, which impairs tumor growth and metastasis via anoikis. Genome-wide analysis in the human prostate cancer cell line
DU-145 identified primary downregulated targets of DZ-50, including genes involved in focal adhesion integrity (fibronectin,
integrin-a6 and talin), tight junction formation (claudin-11) as well as insulin growth factor binding protein 3 (IGFBP-3) and
the angiogenesis modulator thrombospondin 1 (TSP-1). Confocal microscopy demonstrated structural disruption of both
focal adhesions and tight junctions by the downregulation of these gene targets, resulting in decreased cell survival,
migration and adhesion to extracellular matrix (ECM) components in two androgen-independent human prostate cancer
cell lines, PC-3 and DU-145. Stabilization of cell-ECM interactions by overexpression of talin-1 and/or exposing cells to a
fibronectin-rich environment mitigated the effect of DZ-50. Loss of expression of the intracellular focal adhesion signaling
effectors talin-1 and integrin linked kinase (ILK) sensitized human prostate cancer to anoikis. Our findings suggest that DZ-
50 exerts its antitumor effect by targeting the key functional intercellular interactions, focal adhesions and tight junctions,
supporting the therapeutic significance of this agent for the treatment of advanced prostate cancer.
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Prostate cancer is the second most common cancer among men,
with 206,640 men diagnosed and 28,088 dying from prostate
cancer in 2012 [1]. Chemotherapeutic targeting of the androgen
signaling axis in prostate cancer has contributed to the best cancer
survival rate in men. However, a subset of patients become
refractory to androgen ablation therapy by failing apoptosis and
progressing to castration resistant prostate cancer (CRPC) [2].
Prostatic glandular epithelial cells have an intrinsic need for
survival signals imparted by intercellular and cell-extracellular
matrix (ECM) interactions. Focal adhesions are vital for both
normal contact-dependent signaling by normal cells and invasion,
migration and metastasis of malignant cells.
Work from this laboratory identified new anti-tumor action
exerted by drugs classically used for the treatment of benign
prostatic hyperplasia (quinazoline-a1-adrenoceptor antagonists) via
induction of the extrinsic apoptosis cascade (death receptor
activation, caspase-8 cleavage and inhibition of AKT survival
signaling) [3,4,5]. Structural optimization led to the generation of
novel compounds capable of anoikis induction and inhibition of
angiogenesis [6,7]. Anoikis, apoptotic cell death consequential to
insufficient cell-ECM interactions, is a critical component of
angiogenesis and metastasis [8]. Aggressive tumor cells subvert this
mechanism, maintaining survival through dissemination and
seeding in distant organs [9]. Anoikis resistance is closely linked
to increased metastatic potential in many human malignancies,
including prostate cancer [10], renal cell carcinoma [11], breast
cancer [12] as well as tumors of mesenchymal origin [13].
Metastasis necessitates disruption of cellular interactions with
the tumor microenvironment, increased migratory and invasion
capacity and the ability to overcome the pro-apoptotic signals
imparted by diminished intercellular and cell-ECM interactions
[14]. The ECM comprises a diverse network of cytokines
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e86238
impacting cell growth, motility and angiogenesis which can be
made available for cellular use by enzymatic digestion and
remodeling [15]. Transmembrane integrins are characterized by
bidirectional signaling. Oligomerization of integrin proteins about
an ECM substrate induces conformational changes which are
transmitted through the plasma membrane to modulate affinity of
intracellular signaling effectors on cytosolic integrin tails [16]. The
protein aggregates, collectively known as the focal adhesion
complex (FAC), include actin binding proteins (talin-1, vinculin,
vimentin, paxillin, filamin, ect.) which stabilize the cytoskeleton
and kinases (focal adhesion kinase [FAK], integrin-linked kinase
[ILK], and SRC non-receptor tyrosine kinase) which propagate
intracellular signaling to the nucleus. This integrin-mediated
‘‘outside-in’’ signaling cascade controls processes vital to cellular
function and growth as cell cycle progression and differentiation
[17].
As the actin cytoskeletal network undergoes dynamic remodel-
ing/organization, the integrin clustering induces ‘‘inside-out’’
signaling to increase affinity of integrins to the ECM, effectively
establishing a focal adhesion [18]. Upon insufficient integrin-ECM
interactions, cells downregulate members of the anti-apoptotic Bcl-
2 family and upregulate Fas ligand (FasL), inducing anoikis via the
extrinsic apoptosis pathway [19,20]. Talin-1 functionally contrib-
utes to anoikis-resistance and prostate cancer metastasis by
enhancing focal adhesion formation and Akt-survival signaling.
We recently demonstrated a significant correlation between talin-1
overexpression and metastasis in a mouse model of prostate
tumorigenesis and in human prostate cancer progression [10].
Pharmacological exploitation of the a1-adrenoreceptor antag-
onist doxazosinH has led to the generation of novel quinazoline-
based compounds, with the lead agent, DZ-50, having potent
anoikis-inducing effects against cancer cells [6]. DZ-50 suppresses
growth of human prostate cancer xenografts and inhibits their
metastatic potential in vivo by impairing angiogenesis, migration
and invasion [7] through targeting the focal adhesion signaling
axis [11]. The present study investigated the cellular targets of DZ-
50 in androgen-independent human prostate cancer cells.
Genome-wide analysis identified critical effectors of focal adhesion
and tight junction interactions which are targeted by the novel
quinazoline agent.
Materials and Methods
Cell Lines and Reagents
The androgen-independent human prostate cancer cell lines
PC-3 and DU-145 were obtained from the American Type Tissue
Culture Collection and cultured in RPMI 1640 (Invitrogen)
containing 10% fetal bovine serum (Invitrogen) and antibiotics
(PenicilinG/Streptomycin, 50 mg/mL). DU-145 cells were trans-
fected with pEGFP or talin-1 plasmids and cloned under G418
selection (Life Technologies Bethesda Research Laboratories). For
silencing talin-1 expression, the shRNA talin-1 vector (GIPZ
shRNAmir talin-1) was used from Open Biosystems (Hunsville,
AL) and shRNA talin1 DU-145 prostate cancer cells were selected
under puromycin. Polyclonal populations were pooled under
selection, and stable cell lines were characterized by immunoblot-
ting. PC-3 cells were stably transfected with pTRIPZ vector
containing TRE-ILK shRNA (Thermo Scientific). PC-3 shILK
cells were induced with 2 mg/ml doxycycline (Enzo Life Sciences)
for two days. DZ-50, a first-generation doxazosin derivative (Shaw
et al., 2004; Garrison et al., 2007), was used at a concentration of
5 mM dissolved in DMSO for all treatments. Sterile DMSO was
used for control/untreated samples.
Cell Viability Assay
Cell viability was assessed after treatment with 5 mM DZ-50
using the colorimetric MTT (3-[4,5-dimethylthiazol- 2-yl]-2,5
diphenyltetrazolium) assay (1 mg/ml MTT in PBS), and quanti-
fied using a spectrophotometric measurement. Statistical analysis
of 3 independent experiments, each performed in triplicate, is
expressed relative to the untreated control.
Cell Migration Assay
Wounding was inflicted using a sterile pipette tip in confluent
cell monolayers in 6-well plates. After incubation for 12–48 hrs in
the presence of DZ-50 (5 mM), wounded areas were examined by
light microscopy (Axiovert 10, Zeiss). Cells migrating to the
wounded areas were counted under a microscope. Migration
potential was determined as the average number of cells in three
random high-power (4006) fields/well. Numerical data are
obtained from three independent experiments performed in
triplicate and is expressed relative to untreated controls.
Cell Adhesion Assay
Cultures of PC-3 and DU-145 sublines were treated (24 hrs)
with DZ-50 (5 mM) and harvested. Cells (16105/well) were added
to 6-well plates coated with fibronectin (5 mg/ml, BD Biosciences)
and following a 30-mins incubation at 37uC, cells were fixed with
100% (v/v) cold methanol and subjected to image analysis. The
number of adhered cells was counted in three representative
fields/well (4006). Numerical data represent the average of three
independent experiments performed in triplicate and are ex-
pressed relative to untreated controls.
Western Blot Analysis
Human prostate cancer cells, DU-145 and PC-3, were treated
with DZ-50 (5 mM) for sequential time periods and cell lysates
were generated in lysis buffer (150 mmol/L NaCl, 50 mmol/L
Tris (pH 8.0), 0.5% deoxycholic acid, 1% NP40 with 1 mmol/L
phenyl methyl-sulfonyl fluoride, pH 7.4). Protein samples were
subjected to SDS-PAGE and transferred onto Hybond-C mem-
branes (Amersham Pharmacia Biotechnology). Membranes were
incubated overnight at 4uC with the specific primary antibodies:
Akt (Cell Signaling Technology), phosphorylated Akt Ser 473 (Cell
Signaling Technology), GSK-3b (Cell Signaling Technology),
phosphorylated GSK Ser 9 (Cell Signaling Technology), ILK-1
(Cell Signaling Technology), ZO-1 (Invitrogen), Claudin-11 (Santa
Cruz Biotechnology), Talin-1 (Millipore) or Actin (Calbiochem).
Following incubation with the respective primary antibody,
membranes were exposed to horseradish peroxidase–labeled
secondary antibodies and signal was detected with SuperSignal
West Dura Extended Duration Substrate (Pierce) and exposed on
X-ray film. Densitometric analysis was performed using ImageJ
software and values are expressed relative to controls.
Gene (qRT-PCR) Analysis
RNA was isolated from cell lysates using TRIzol Reagent
(Ambion) and Pure Link RNA Mini Kit (Invitrogen) according to
the manufacturer. After homogenization and phase separation by
centrifugation (12,000 g, 4uC), RNA was precipitated with
isopropanol. Samples were centrifuged (12,000 g, 4uC) and cDNA
was synthesized using RNA (1 mg) and the Reverse Transcription
System (Promega). DNA array analysis was conducted at the
University of Kentucky Microarray Core Facility using Affymetrix
GeneChip Technology. The transcripts were evaluated by ABI
7700 Sequence Detection System (Applied Biosystems Inc.); each
treatment (5 mM DZ-50, 9 hrs) was performed in triplicate.
DZ-50 Impairs Prostate Cancer Interactions
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For the RT-PCR analysis, RNA (1 mg) was subjected to reverse
transcription using the Reverse Transcription System (Promega).
The following primers were designed (Sigma) for the SYBR Green
quantitative real time PCR (qRT-PCR) system:Fibronectin-1 (F:





TGGGAATGGGACGCAGTT-39), and ZO-1 (F: 59-
GGAGCTGCGCTTACCACACT-39, R: 59-
TTTGCTCCAACGAGATAATTTGG-39). The following prim-
ers were obtained for the TaqMan qRT-PCR system (Invitrogen):
18 s ribosomal RNA (rRNA), Thrombospondin-1, IGF-BP3,
Claudin-11, Snail. cDNA was used for qRT-PCR analysis
according to respective SYBR Green and TaqMan protocols
(Bio-Rad). For the qRT-PCR experiments, each sample was
analyzed in triplicates and data represent average values from
three independent experiments. Numerical data for transcript
levels were normalized to 18 s rRNA in controls and expressed
relative to untreated controls.
Immunofluorescence Analysis
Cells plated in 4-well chamber slides coated with Fibronectin
(5 mg/ml, BD Biosciences) were exposed to DZ-50 treatment
(5 mM) for 12 hrs. Cells were then fixed in 100% (v/v) methanol,
and after blocking at 4uC (5% NGS, 0.3% Triton X), were
exposed to the primary antibody (4uC, overnight). The following
specific antibodies were used: ILK-1 (Cell Signaling Technology),
ZO-1 (Invitrogen), Claudin-11 (Santa Cruz Biotechnology), Snail
(Cell Signaling Technology), Talin (Millipore). Cells were then
incubated with fluorochrome-conjugated secondary antibody
(Invitrogen) (2 hrs, room temperature) and subjected to confocal
microscopy using an Olympus FV1000 Confocal Microscope
v1.21. and software version FV10-ASW 3.1.
Microarray Analysis
shTalin or vector DU-145 human prostate cancer cells were
treated with DZ-50. RNA samples from cells before or after (9 hrs)
treatment were submitted to the University of Kentucky Micro-
array core facility for analysis on Affymetrix Human Gene 1.0 ST
arrays (Affymetrix, Santa Clara, CA). The experiment under each
condition was performed in duplicate.
Statistical Analysis
Microarray data were normalized by using RMA and analyzed
by using two-way analysis of variance (ANOVA) models, with
genotype (shTalin or vector) and treatment (before or after) as the
two factors. Contrasts were generated to evaluate changes in
mRNA expression between treated versus untreated in vector cells.
False discovery rate (FDR) and the associated q-values were
calculated by using the method in REF. Differentially expressed
genes were determined based on FDR,20% and fold
change.1.5. Statistical analyses for data from all other experi-
ments were performed based on one-sample or two-sample t-tests
as appropriate. At P,0.05 values were considered statistically
significant.
Results
Novel Quinazoline DZ-50 Induces Prostate Cancer Cell
Anoikis
The anoikis-inducing effect of the lead quanazoline compound
DZ-50 was investigated in human prostate cancer cell lines
variably expressing the FAC proteins, talin-1 and ILK. Stable
transfection of DU-145 cells resulted in knockdown of talin (DU-
145 shTalin) and overexpression of talin (DU-145 Talin+) (Fig.1,
panel A). PC-3 cells expressing an inducible shILK vector
demonstrated effective downregulation of ILK upon induction
with doxycycline for 48 hrs (Fig.1, panel A). There was a time-
dependent decrease in cell viability in response to DZ-50 (Fig.1,
panel B). Loss of ILK and talin expression in PC-3 and DU-145
prostate cancer cells respectively resulted in enhanced sensitivity to
DZ-50, while talin overexpression suppressed anoikis. The data on
panel C (Fig. 1) show that in response to DZ-50, prostate cancer ell
migration is significantly increased. Loss of either ILK (PC-3 cells),
or talin (DU-145 cells), inhibited cell migration, while further
enhanced the effect of DZ-50. Loss of either ILK or talin
independently led to a significant reduction in cell adhesion to
fibronectin (Fig.1, panel D).
Identification of Molecular Targets of Lead Quinazoline
Genome-wide analysis of gene expression in the human prostate
cancer cell line DU-145 was used to identify primary targets of
DZ-50 (Fig. 2). The heat map from the gene array analysis after
treatment of prostate cancer cells with DZ-50 (for 9 hrs) is shown
on Figure 2 (panel A). DZ-50 resulted in a significant downreg-
ulation of genes encoding plasma membrane associated proteins,
including regulators of ECM (fibronectin and integrin-a6), and tight
junctions (claudin-11), insulin growth factor binding protein 3
(IGFBP-3), as well as the angiogenesis mediator thrombospondin 1
(TSP-1). To validate the panel of candidate gene targets identified
by the gene array molecular profiling, we subsequently conducted
quantitative real time PCR (qRT-PCR) analysis (Fig. 2, panel B).
Exposure of DU-145 cells to DZ-50 (3 and 9 hrs) led to a
significant inhibition of expression for a selected gene signature
identified the array analysis (Fig.2, panel A), including genes
encoding for key focal adhesion signaling effectors, intracellularly
(talin) and extracellularly (fibronectin) and tight junction proteins
(Claudin-11 and ZO-1). A transcriptional mediator of EMT, Snail,
is also reduced by DZ-50. The chemical structure of the
quinazoline-based compound DZ-50, is shown on panel C (Fig. 2).
DZ-50 Targets Vital Cellular Interactions in Prostate
Cancer Cells
To characterize the effect of DZ-50 on tight junctions (TJ) the
co-localization of ZO-1 and Claudin-11, two proteins essential for
these intercellular interactions, was assessed using fluorescent
confocal microscopy in two different human prostate cancer cell
lines, PC-3 and DU-145 (Fig. 3, panels A and B respectively).
Treatment with DZ-50 (12 hours) markedly decreased Claudin-11
expression (red) in both parental cell lines, resulting in appreciable
impairment of TJ formation. Subcellular localization of ZO-1
(green) to the plasma membrane resulted in response to DZ-50.
Cells expressing functional loss of the focal adhesion proteins ILK
(PC-3 shILK) and talin (DU-145 shTalin) maintained some
Claudin-11 expression despite treatment with DZ-50 relative to
the respective parental cell lines (white arrows). This expression of
Claudin-11 complexes with ZO-1 at the plasma membrane as
poorly defined, punctate TJ complexes is shown on Figure 3
(composite images, panels A and B). In response to DZ-50, there
was a time-dependent upregulation in ZO-1 protein levels. ZO-1
expression was inversely correlated with expression of focal
adhesion protein ILK (Fig. 3, panels C and D). Western blot
analysis revealed that talin overexpression in DU-145 cells resulted
in reduced ZO-1 protein levels, while downregulation of talin was
associated with increased ZO-1 (Fig. 3, panels E, F).
DZ-50 Impairs Prostate Cancer Interactions
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Fluorescent microscopy was used to examine the effect of DZ-
50 on focal adhesion dynamics in the two different human prostate
cancer cell lines PC-3 (Fig. 4) and DU-145 (Fig. 5). The results on
Figure 4 indicate that in response to DZ-50 (12 hrs), there was a
significant decrease in talin (red) and ILK (green) protein
expression, compromising the focal adhesion integrity (composite
images Fig. 4, panel A; DAPI-blue nuclear staining). To determine
the impact of ECM on the cellular response to DZ-50, PC-3 cells
were cultured in the presence of fibronectin. The presence of
fibronectin facilitated focal adhesion stabilization and sustained
expression of talin and ILK, rescuing prostate cancer cells from the
anoikis effect of DZ-50 (composite images Fig. 4, panels A and B).
Functional loss of ILK in PC-3 cells (Fig. 4, panel B) resulted in
FAC instability with concomitant downregulation of talin relative
to parental PC-3 cells (Fig. 4, panel A). Treatment of shILK cells
with DZ-50 resulted in complete abrogation of FAC signaling, a
phenomenon that was partially rescued in the presence of
fibronectin.
We subsequently examined the consequences of talin reduction
on prostate cancer cell focal adhesion integrity and their sensitivity
to DZ-50. Confocal microscopy images shown on Figure 5, reveal
that the presence of fibronectin antagonized the anoikis effect of
the drug on focal adhesions in DU-145 cells (Fig. 5, panel A) under
functional talin levels. Silencing of talin in prostate cancer cells
however resulted in the focal adhesion complex formation to be
abolished even in the presence of fibronectin (Fig. 5, panel B).
There were no so significant differences in focal adhesions in the
DU-145shTalin cells.
Figure 1. ILK and talin mediate DZ-50 action on prostate cancer cell death and migration. Panel A, right, Western blot revealing that shILK
transfectant PC-3 cells exhibit total loss of ILK-1 protein expression relative to vector control cells upon induction with doxycycline (48 hrs). On the
left, DU-145 cells in which talin has been silence (shTalin) or overexpressed (Talin+), exhibit significant reduction or marked overexpression of talin
protein levels respectively, relative to parental DU-145 cells. Panel B, DZ-50 treatment leads to a significant decrease in prostate cancer cell viability in
a time-dependent fashion. Loss of ILK1 enhances the DZ-50 induced loss of cell viability; in contrast talin overexpression confers resistance to DZ-50
induced cell death. Panel C, DZ-50 significantly reduces prostate cancer cell migration. Loss of talin results in a significant reduction of prostate cancer
cell migration compared to parental control DU-145 cells. In response to DZ-50, talin overexpression restores cell migratory ability to the levels of
untreated cells. Panel D, Functional loss of ILK in PC-3 prostate cancer cells and loss talin in DU-145 cells significantly impairs the ability of the
respective prostate cancer cells to adhere to fibronectin (ECM). Talin overexpression markedly enhances prostate cancer cell adhesion to fibronectin,
compared to parental DU-145 and DU-145 shTalin cells. Statistical significance was set at *p,0.05.
doi:10.1371/journal.pone.0086238.g001
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DZ-50 Impairs Downstream Intracellular Survival
Signaling
To investigate the consequences of DZ-50 on the intracellular
signaling downstream of the focal adhesion complex and tight
junctions, AKT and GSK3b were profiled as intermediate survival
signaling effectors [11,21]. As shown on Figure 6 targeting of these
cellular interactions by DZ-50 results in marked reduction of
phosphorylation of both AKT and GSK3b within 3–6 hrs of
treatment (Panels B and C). Overexpression of talin in prostate
cancer cells induced phosporylation of Akt and GSK-3b, thus
leading to enhanced survival and resistance to the action of DZ-50.
In contrast, DU-145 cells with reduced talin levels, exhibited
decreased Akt and GSK3b phosphorylation (Fig. 6, panel C).
Discussion
Genome-wide analysis of gene expression in DU-145 human
prostate cancer cells revealed downregulation of promising anti-
tumor targets by the novel quinazoline derivative DZ-50,
including EMT-associated genes (integrin-a6, fibronectin and
talin), angiogenesis associated genes (TSP-1), genes associated with
intercellular TJs (claudin-11 and 14) as well as serine threonine
kinase 31 (TSK31) and insulin growth factor binding protein 3
(IGFBP-3). Confocal microscopy examination confirmed that DZ-
50 targets critical proteins involved in the formation of both TJs
and focal adhesions, consequently impairing extracellular interac-
tions, actin cytoskeleton integrity and pro-survival intracellular
signaling. We previously established the in vivo antitumor action of
Figure 2. Genes targeted by DZ-50 in prostate cancer cells. Panel A, Heat map of differentially expressed genes in DU-145 human prostate
cancer cells before and after treatment with DZ-50 (9 hrs). We identified 17 markedly downregulated genes following treatment with DZ-50 (9 hrs),
including genes encoding for ECM regulators fibronectin and integrin a6, tight junction mediator Claudin-11 and angiogenesis signaling effector
thrombospondin 1. (fold change .1.5, false discovery rate ,20%). Panel B, Validation of gene expression using qRT-PCR after DZ-50 treatment of
prostate cancer cells (5 mM) for 3 and 9 hrs. A significant reduction in mRNA relative to untreated cells was detected for genes involved in ECM-focal
adhesion signaling components (fibronectin, integrin-a6 and talin), tight junctions (claudin-11), angiogenesis (thrombospondin-1) and EMT (Snail).
*indicates significant difference at p,0.05. Panel C, Molecular structure of the Doxazosin derivative, DZ-50.
doi:10.1371/journal.pone.0086238.g002
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DZ-50 in two human androgen-independent prostate cancer
xenografts, PC-3 and DU-145 [7]. Recent evidence suggested that
talin confers anoikis resistance in prostate cancer cells towards
metastases, via its ability to stabilize focal adhesions and propagate
focal adhesion complex signaling through the Akt survival
signaling [10]. In the present study, using two different andro-
gen-independent human prostate cancer cell lines and DU-145
and PC-3, as in vitro experimental systems, we demonstrated that
two distinct intracellular focal adhesion complex components, talin
and ILK, are targeted by the lead quinazoline DZ-50 (Fig. 6).
Talin overexpression confers insensitivity to DZ-50, while loss of
talin reduced tumor cell survival, migration and adhesion,
sensitizing prostate cancer cells to the anoikis effect by DZ-50.
The phenotypic changes and increased sensitivity to DZ-50
observed in DU-145 cells with low talin expression, and PC-3 cells
harboring loss of ILK function, support a regulatory role for these
two critical components of the focal adhesion complex in cancer
cell anoikis resistance. Figure 6 illustrates a mechanistic schema of
DZ-50 mediated anoikis signaling. Tight junctions are located on
the apicobasal plasma membrane, forming a selectively permeable
Figure 3. Disruption of tight junctions in human prostate cancer cells by lead agent DZ-50. Characteristic confocal microscopy images of
PC-3 cells (Panel A) and DU-145 cells (Panel B). Treatment with DZ-50 (12 hrs, 5 mM) decreases Claudin-11 expression and inhibits tight junction
formation. Tight junctions complexes (arrows), characterized by colocalization of the tight junction proteins Claudin-11 (red) and ZO-1) (green) is
completely abrogated by DZ-50. In PC-3 shILK and DU-145shTalin cells there is weak formation of TJ complexes (arrow heads), in response to DZ-50.
DAPI (blue) is used for nuclear detection (Panels A and B). Magnification x100. Panels C–F, Western blots and respective densitometric analysis
revealing the expression of TJ protein ZO-1 in response to DZ-50 in PC-3 (Panels C and D) and DU-145 (Panels E and F) prostate cancer cell lines.
doi:10.1371/journal.pone.0086238.g003
Figure 4. Disruption of focal adhesions in prostate cancer cells by DZ-50. PC-3 prostate cancer cells and PC-3 shILK cells harboring loss of
ILK (panels A and B, respectively) were treated with DZ-50 (12 hrs, 5 mM) in the absence or presence of fibronectin-ECM. Fluorescent images reveal
the co-localization of focal adhesion regulators talin (red) and ILK (green) to be disrupted by DZ-50 treatment, compared to untreated controls. DAPI
(blue) is used for nuclear detection. Silencing ILK expression leads to reduced detection of its primary upstream partner, talin and subsequent
disruption of focal adhesions (Panel B), relative to parental PC-3 cells (Panel A, composite, focal adhesions identified in yellow). Prostate cancer cells
grown on a fibronectin-coated substrate (ECM integrity) stabilize the focal adhesion complex and diminish the targeting ability of DZ-50 on these
substrates in both PC-3 parental and PC-shILK cells. Magnification x100.
doi:10.1371/journal.pone.0086238.g004
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barrier essential for fluid and electrolyte balance. Claudins are
transmembrane adhesion proteins that span the intercellular space
to form homo- or heterodimers on opposing cells [22]. Cytoplas-
mic tails of claudins interact with actin-stabilizing proteins, zonula
occludins (ZO) [23]. Claudin-1 upregulation is associated with
colorectal tumor progression via anoikis resistance, evidence
linking anoikis to tight junctions impacted by Bcl-2 and AKT
survival signaling [24].
Targeting of critical intra- and extracellular focal adhesion
components in prostate cancer cells, specifically talin, ILK,
integrin-a6 and fibronectin by lead agent DZ-50, lifts anoikis
resistance by inhibiting downstream survival signaling by AKT
and GSK3b (Fig. 6). Our findings are in accordance with evidence
supporting that concomitant activation of FAK and AKT (by
transforming growth factor-b1) confers an anoikis-resistant phe-
notype to myofibroblasts [25]. Moreover, activation of AKT
signaling can directly challenge AR activity, functionally implicat-
ing this pathway as a contributor to therapeutic resistance to
androgen ablation and emergence of CRPC [26]. ECM compo-
nents facilitate cellular interactions towards stabilization of focal
adhesions; our findings suggest that DZ-50 can target fibronectin
and integrin expression, disrupting the ECM and ultimately
intracellular focal adhesion signaling. Integrins and FAC signaling
have been implicated in prostate cancer metastasis to bone
through the stabilization of collagen subunits in ECM [27].
Expression profiling a and b integrin subunits revealed upregula-
tion of specific isoforms in prostate tumor metastasis [16,28,29],
reinforcing a ‘‘sniper-targeting’’ attack against ECM-integrin-FAC
to stop metastatic spread.
Epithelial-mesenchymal transition (EMT) confers stem cell
properties and leads to acquisition of a migratory, invasive
mesenchymal phenotype [30]. A characteristic hallmark of EMT
Figure 5. Contribution of Talin-1 to prostate cancer cell anoikis resistance. DU-145 (panel A) and DU-145 shTalin (panel B) were cultured in
the absence or presence of fibronectin-coating and treated with DZ-50; cells were subsequently subjected to confocal microscope for detection of
talin (red), ILK (green), and focal adhesions (yellow). Nuclei were detected by DAPI staining (Blue). DZ-50 decreased focal adhesion formation through
the targeting of talin and ILK. This effects was abrogated by the presence of fibronectin-ECM, which conferred resistance to DZ-50 (Panel A). Loss of
talin resulted in reduced co-localization with ILK and disappearance of focal adhesions in DU-145 shTalin cells (Panel B). Magnification x100. Panels C–
E, Western blot and quantitative analysis of the time-dependent effect of DZ-50 on downstream cell survival signaling. DZ-50 leads to
dephosphorylation of survival signaling effectors AKT (Panel D) and GSK-3b (Panel E). Talin overexpression confers resistance to DZ-50 anoikis effect
by sustaining activation/phosphorylation of AKT and GSK-3b signaling.
doi:10.1371/journal.pone.0086238.g005
Figure 6. DZ-50 induces anoikis by targeting focal adhesion survival signaling. DZ-50 targets cell-cell interactions (tight junctions) and cell-
ECM interactions (focal adhesions) to decrease intracellular survival signals and disrupt actin cytoskeletal integrity to induce anoikis. Stabilization of
focal adhesion complex signaling by ECM components and elevated talin, enhances bidirectional integrin signaling, resulting in cellular resistance to
anoikis (right). DZ-50 targets extracellular, intercellular and intracellular adhesions and signaling molecules to induce anoikis (left).
doi:10.1371/journal.pone.0086238.g006
DZ-50 Impairs Prostate Cancer Interactions
PLOS ONE | www.plosone.org 9 January 2014 | Volume 9 | Issue 1 | e86238
is loss of E-cadherin, causing adherens junction breakdown, which
suffices to circumvent anoikis in the tumor microenvironment
[31]. Dynamic cycles of EMT-MET can direct the androgen
signaling to promote invasive behavior and therapeutic resistance
in preclinical models of prostate tumor progression towards CRPC
[30,32,33]. The role of tight junctions in anoikis and metastasis has
not been well understood, despite intense interrogations of the
impact of loss of cell-cell interactions in invasive and de-
differentiation responses to extracellular stimuli. Overexpression
of claudins has been implicated in a variety of tumors including
prostate, breast, ovarian and pancreatic cancer [34]. Claudin-1
engages the downstream PI3K/AKT survival pathway, thus
contributing to anoikis resistance in colon cancer [24,35]. Our
molecular analysis identified that the lead new quinazoline, DZ-
50, disrupts tight junction formation in human prostate cancer
cells by downregulating Claudin-11, a critical TJ protein, also
contributing to the actin cytoskeleton [36,37]. Considering the
redundant role of maintaining actin cytoskeletal integrity via the
AKT pathway shared by tight junctions and focal adhesions,
functional interference and potential structural collapse of both
cellular-interaction platforms by DZ-50, may contribute to a
compounded anti-tumor effect (Fig. 6). Putative targets in cell
adherence junctions mediated by E-cadherin in EMT control may
also be considered [38].
In summary, the present data identify the anoikis action of the
novel lead compound DZ-50 in prostate cancer cells, by disrupting
vital cellular interactions navigated by Claudin-11 (TJ) and talin
(FAC), in the microenvironment. Elevated Talin may be
pharmacologically linked to chemotherapeutic tolerance to drugs
that target cell-cell and cell-ECM interactions, pointing to the
therapeutic value of DZ-50 in targeting metastatic CRPC.
Ongoing clinical trials aim at therapeutic optimization of
combined targeting of the AR axis with selective small molecule
inhibitors of angiogenesis (tasquinomod, bevacizumab), IGF
signaling (cixutumumab), tyrosine kinase signaling (dasatinib,
sunitinib, cabozantinib) [2] and proteasome degradation [39].
The anoikis action of DZ-50, enables a pharmacologic platform
for development of novel strategies, as well as therapeutic
optimization of existing regimes for advanced CRPC [40].
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